Trials with NGF for Alzheimer's disease had gained some degree of success, but the high molecular weight of the NGF protein seems to suggest that it could not cross the blood-brain barrier [4]. This evidence concerns the gene NGF and early-onset autosomal dominant Alzheimer disease.